Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study

Respiration

Volumn 89, Issue 3, 2015, Pages 201-207

  Isshiki, Takuma ^a   Sakamoto, Susumu ^a   Kinoshita, Arisa ^a   Sugino, Keishi ^a   Kurosaki, Atsuko ^b   Homma, Sakae ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b Japan Anti Tuberculosis Association   (Japan)

Author keywords

Acute exacerbation; Idiopathic pulmonary fibrosis; Recombinant human soluble thrombomodulin

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIFIBROTIC AGENT; CYCLOSPORIN A; D DIMER; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PIRFENIDONE; RECOMBINANT THROMBOMODULIN; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ACUTE DISEASE; ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS; AGED; ANTIBIOTIC THERAPY; AUTOPSY; BLEEDING; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; HEMATURIA; HEMOPTYSIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; LUNG FUNCTION TEST; MAINTENANCE DRUG DOSE; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; DOSE RESPONSE; EPIDEMIOLOGY; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; MORTALITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRENDS;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; JAPAN; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84925256449     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000369828     Document Type: Review

References (29)

1. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Quernheim JM, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ: Acute exacerbation of idiopathic fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
2. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K: Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808-1812.
3. Agarwal R, Jindal SK: Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008; 19: 227-235.
4. Inase N, Sawada M, Ohtani Y, Miyake S, Isogai S, Sakashita H, Miyazaki Y, Yoshizawa Y: Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003; 42: 565-570.
5. Homma S, Sakamoto S, Kawabata M, Kishi K, Tsuboi E, Motoi N, Yoshimura K: Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005; 44: 1144-1150.
6. Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K: Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010; 49: 109-115.
7. Seo Y, Abe S, Kurahara M, Okada D, Saito Y, Usuki J, Azuma A, Koizumi K, Kudoh S: Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2006; 45: 1033-1038.
8. Hara S, Ishimoto H, Sakamoto N, Mukae H, Kakugawa T, Ishimatsu Y, Mine M, Kohno S: Direct hemoperfusion Using Immobilized polymyxin B in patients with rapidly progressive interstitial pneumonias: a retrospective study. Respiration 2011; 81: 107-117.
9. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H: Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005: 128: 1475-1482.
10. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430.
11. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchiyama T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
12. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A: Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
13. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS: Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299:L3-L7.
14. Ebina M, Taniguchi H, Miyasho T, Yamada S, Shibata N, Ohta H, Hisata S, Ohkouchi S, Tamada T, Nishimura H, Ishizaka A, Maruyama I, Okada Y, Takashi K, Nukiwa T: Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm Med 2011; 2011: 916486.
15. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Anchochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi J, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: An official ATS/ERS/ JRS/ALAT statement. Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
16. Japanese Respiratory Society's Committee Formulating Diagnosis and Treatment Guideline for Diffuse Lung Diseases. Clinical Diagnostic and Treatment Guidance for Idiopathic Interstitial Pneumonias. Tokyo, Nankodo, 2011, pp 67-73.
17. Akira M, Kozuka T, Yamamoto S, Sakatani M: Computed tomography findings of acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 372-378.
18. Wang H, Vishnubhaket JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126: 389-392.
19. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004; 170: 1310-1316.
20. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, doubleblind clinical trial. J Thromb Haemost 2007; 5: 31-41.
21. Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, Nakagawa T: Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J 2013; 11: 3.
22. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T: Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011; 15:R123.
23. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, Kuwagata Y, Shimazu T, Hamasaki T, Fujimi S: Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012; 72: 1150-1157.
24. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, Hamasaki T, Shimazu T: Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013; 39: 644-652.
25. Noth I, Anstrom KJ, Calvert SB, Andrade JD, Flaherty KR, Glazer C, Kaner RJ, Olman MA: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
26. Song JW, Hong S-B, Lim C-M, Koh Y, Kim DS: Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-363.
27. Castro DJ, Perez-Rodriguez E, Montaner L, Flores J, Nuevo GD: Diagnostic value of Ddimer in pulmonary embolism and pneumonia. Respiration 2001; 68: 371-375.
28. Blancal VS, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, Denis D, Cohen Y, Vincent F, Valeyre D, Naccache JM: Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration 2012; 83: 28-35.
29. Mohri M, Sugimoto E, Sata M, Asano T: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation - a comparison with other anticoagulants. Thromb Haemost 1999; 82: 1687-1693.